| Neulasta (pegfilgrastim) / Roche |
ChiCTR1800019807: A prospective, open, single arm study for the efficacy and safty analysis of pegfilgrastim in preventing neutropenia in patients with head and neck cancer after concurrent chemoradiotherapy |
|
|
| Recruiting | 4 | 20 | | 48h after chemotherapy, PEG-rhG-CSF, subcutaneous injection, once per cycle | General Hospital of Chinese People's Liberation Army; General Hospital of Chinese People's Liberation Army, CSPC zhongcheng Pharmaceutical Logistics Co., Ltd. | head and neck cancer | | | | |
ChiCTR1800020351: A multicenter, open, randomized controlled study for the efficacy and safty analysis of pegfilgrastim in preventing neutropenia in patients with non-small cell lung cancer after concurrent chemoradiotherapy |
|
|
| Recruiting | 4 | 196 | | Subcutaneous injection of PEG-rhG-CSF 48 hours after the chemotherapy ;Subcutaneous injection of rhG-CSF when WBC<2.0×10^9/L or ANC≤1.0×10^9/L during the chemotherapy | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, CSPC Baike (Shandong) Biological Pharmaceutical Co., Ltd. | Non-small cell lung cancer | | | | |
ChiCTR1900021410: Efficacy and safety of pegfilgrastim for prophylactic chemoradiotherapy in patients with cervical cancer |
|
|
| Recruiting | 4 | 15 | | Subcutaneous injection of pegfilgrastim 24-72 hours after chemotherapy | General Hospital of Chinese People's Liberation Army; General Hospital of Chinese People's Liberation Army, CSPC Baike (Shandong) Biological Pharmaceutical Co., Ltd. | Cervical cancer | | | | |
ChiCTR1900021399: Real-world study for the efficacy and safety of pegfilgrastim in preventing neutropenia after chemotherapy in breast cancer patients |
|
|
| Not yet recruiting | 4 | 1000 | | Use Jin Youli within 24 hours and within 12 days of the next chemotherapy | Tianjin Cancer Hospital; Tianjin Cancer Hospital, CSPC Baike (Shandong) bio-pharmaceutical co. LTD | Breast cancer | | | | |
ChiCTR1900027961: Real-world study for pegfilgrastim(Jinyouli) in preventing neutropenia after chemotherapy in patients with ovarian cancer |
|
|
| Not yet recruiting | 4 | 500 | | After 24 hours of chemotherapy, and 12 days before the next cycle of chemotherapy, subcutaneous injection of Jinyouli (PEG-rhG-CSF) 6mg | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, China Shijiazhuang Pharmaceutical Company (CSPC) Baike (Shandong) Biopharmaceutical Co. Ltd. | ovarian cancer | | | | |
ChiCTR1900024592: A prospective, open, single arm study for the efficacy and safty of pegfilgrastim in preventing neutropenia in patients with gynecologic tumors |
|
|
| Not yet recruiting | 4 | 304 | | short-acting rhG-CSF was given for remedial treatment, 5μg/kg/day until neutrophil count >=2.0x10^9/L ;no any G-CF was given ;Give patients PEG-rhG-CSF subcutaneously once in a cycle,6mg for patient's weight ≥ 45kg, 3mg for patient's weight <45kg (Note: after injection of PEG-rhG-CSF, the next chemotherapy start time shoule be more than 12 days) ;Patients were given rhG-CSF 5μg/kg/day for treatment until the patient's blood neutrophil count was >=2.0x10^9/L | TongJi Hospital of TongJi Mediical College, Huazhong University of Science and Technology; TongJi Hospital of TongJi Mediical College, Huazhong University of Science and Technology, CSPC Baike (Shangdong) Biological Phamaceutical Co.,Ltd. | Gynecologic Oncology | | | | |
ChiCTR2100052432: A phase II clinical study of pegfilgrastim in the prevention of neutropenia after chemotherapy in patients with digestive tract cancer |
|
|
| Recruiting | 4 | 48 | | Patients participate in two cycles of dosing | the Fourth Hospital of Hebei Medical University; the Fourth Hospital of Hebei Medical University, None | Gastrointestinal neoplasm | | | | |
REaCT-5G, NCT04781959: A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy |
|
|
| Active, not recruiting | 4 | 233 | Canada | Filgrastim, Neupogen, Pegfilgrastim, Neulasta | Ottawa Hospital Research Institute | Early-stage Breast Cancer | 10/23 | 12/23 | | |
NEUTHREE, NCT05949333: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy |
|
|
| Recruiting | 4 | 100 | RoW | Eflapegrastim, Rolvedon, Eflapegrastim-xnst, HM-10460A, SPI-2012 | Eunseong Medical Foundation Good GANG-AN HOSPITAL, Hanmi Pharmaceutical Company Limited | Breast Neoplasms | 01/25 | 07/25 | | |
REaCT-OGF, NCT05753618: Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy |
|
|
| Recruiting | 4 | 240 | Canada | Granulocyte Colony-Stimulating Factor (G-CSF), Filgrastim, Pegfilgrastim, Omission of Granulocyte Colony-Stimulating Factor (G-CSF) | Ottawa Hospital Research Institute | Early-stage Breast Cancer | 10/25 | 10/25 | | |
